このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
NGM Biopharmaceuticals 過去の業績
過去 基準チェック /06
NGM Biopharmaceuticalsの収益は年間平均-35.7%の割合で減少していますが、 Pharmaceuticals業界の収益は年間 減少しています。収益は年間0.4% 26.1%割合で 減少しています。
主要情報
-35.7%
収益成長率
-26.0%
EPS成長率
| Pharmaceuticals 業界の成長 | 6.0% |
| 収益成長率 | -26.1% |
| 株主資本利益率 | -95.8% |
| ネット・マージン | -3,223.3% |
| 前回の決算情報 | 31 Dec 2023 |
最近の業績更新
Recent updates
What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You
Dec 19
We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate
Oct 05Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates
Aug 09Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky
Jun 27NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't
Apr 17We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully
Dec 20NGM Biopharma sinks ~72% after phase 2 trial of its eye degeneration treatment fails
Oct 17NGM Biopharmaceuticals appoints CFO Siobhan Nolan Mangini to the additional role of President
Jun 30NGM Biopharmaceuticals: Eye Disorder Data Due Second Half Of 2022
Jun 21Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
Jun 15Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week
May 09NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad
Apr 26Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
Feb 21We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely
Nov 08Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
Jul 09NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Mar 06We're Not Very Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate
Mar 02Update: NGM Biopharmaceuticals (NASDAQ:NGM) Stock Gained 56% In The Last Year
Jan 26
NGM Bio gives update on 2021 plans and data timeline
Jan 12収支内訳
収支内訳
NGM Biopharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 31 Dec 23 | 4 | -142 | 37 | 0 |
| 30 Sep 23 | 22 | -151 | 39 | 0 |
| 30 Jun 23 | 30 | -170 | 41 | -15 |
| 31 Mar 23 | 37 | -178 | 41 | 1 |
| 31 Dec 22 | 55 | -163 | 41 | 0 |
| 30 Sep 22 | 58 | -153 | 40 | 0 |
| 30 Jun 22 | 69 | -135 | 39 | 80 |
| 31 Mar 22 | 77 | -125 | 39 | 1 |
| 31 Dec 21 | 78 | -120 | 37 | 0 |
| 30 Sep 21 | 77 | -121 | 35 | 0 |
| 30 Jun 21 | 82 | -122 | 32 | 0 |
| 31 Mar 21 | 85 | -111 | 29 | 4 |
| 31 Dec 20 | 87 | -102 | 27 | 0 |
| 30 Sep 20 | 99 | -90 | 26 | 0 |
| 30 Jun 20 | 97 | -72 | 25 | 0 |
| 31 Mar 20 | 102 | -54 | 25 | 0 |
| 31 Dec 19 | 104 | -43 | 24 | 0 |
| 30 Sep 19 | 120 | -13 | 22 | 0 |
| 30 Jun 19 | 119 | -9 | 22 | 0 |
| 31 Mar 19 | 116 | -5 | 19 | 0 |
| 31 Dec 18 | 109 | 0 | 17 | 0 |
| 30 Sep 18 | 81 | -17 | 16 | 0 |
| 30 Jun 18 | 80 | -12 | 15 | 0 |
| 31 Mar 18 | 77 | -13 | 15 | 0 |
| 31 Dec 17 | 77 | -14 | 15 | 0 |
| 31 Dec 16 | 86 | -7 | 12 | 0 |
質の高い収益: NGMは現在利益が出ていません。
利益率の向上: NGMは現在利益が出ていません。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: NGMは利益が出ておらず、過去 5 年間で損失は年間35.7%の割合で増加しています。
成長の加速: NGMの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。
収益対業界: NGMは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( 19.9% ) と比較することは困難です。
株主資本利益率
高いROE: NGMは現在利益が出ていないため、自己資本利益率 ( -95.79% ) はマイナスです。